<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878838</url>
  </required_header>
  <id_info>
    <org_study_id>HV-AVO1</org_study_id>
    <nct_id>NCT01878838</nct_id>
  </id_info>
  <brief_title>The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.</brief_title>
  <official_title>A Prospective Randomized Controlled Clinical Trial Comparing the Intra-operative Effects, Safety, Efficacy and Performance of Two Commercially Available Laser Systems in Patients Undergoing Femtosecond Laser-Assisted Cataract Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steve H. Linn, OD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoopes Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares two FDA approved Cataract Lasers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to systematically evaluate the performance of two commercially
      available and FDA cleared femtosecond laser systems in patients undergoing femtosecond
      laser-assisted cataract surgery. Objective data on the repeatability and accuracy of the
      studied parameters will be gathered and reported as endpoints of the study.

      The two systems studied are the Catalys™ Precision Laser System (OptiMedica, CA, USA) and the
      LenSx® Laser System (Alcon Laboratories, Inc., Fort Worth, TX).

      Published data have suggested that the femtosecond laser is a useful tool for cataract
      surgery.

      This study is to determine whether differences or similarities exist in specific treatment
      parameters achieved with two FDA cleared and commercially available femtosecond laser
      cataract surgery platforms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Dissipated Energy</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The total amount of phacoemulsification energy delivered during the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Laser Capsulotomy</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Did the laser perform a complete capsulotomy with no tags or untreated segments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Nuclear Sclerosis of the Lens</condition>
  <condition>Posterior Subcapsular Cataract</condition>
  <condition>Cortical Cataract</condition>
  <arm_group>
    <arm_group_label>Catalys Treated Eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LenSx Treated Eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser</intervention_name>
    <description>Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.</description>
    <arm_group_label>Catalys Treated Eyes</arm_group_label>
    <other_name>Optimedica Catalys Precision Laser System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser</intervention_name>
    <description>Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.</description>
    <arm_group_label>LenSx Treated Eyes</arm_group_label>
    <other_name>Alcon LenSx Laser System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have grade 2 to 4 nuclear sclerotic and or cortical or posterior subcapsular cataracts
             with visual impairment.

          -  Pupillary dilation of at least 6.0 mm

          -  Axial length between 21 mm to 26 mm

          -  Age ≥ 22 years of either gender

          -  Require laser assisted corneal incisions, capsulotomy and nucleus segmentation

          -  Understand and sign a written Informed Consent form

          -  Be able to comply with the treatment and follow-up schedule

        Exclusion Criteria:

          -  Enrolment in another drug or device study within the prior 3 months

          -  History of ocular trauma

          -  Acute or chronic disease or illness that would increase risk or confound study results
             (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.)

          -  Uncontrolled systemic or ocular disease

          -  Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies, severe
             corneal opacities, significant corneal edema, etc)

          -  Diminished aqueous clarity that obscures OCT imaging of the anterior lens capsule

          -  Corneal ring and/or inlay implant(s)

          -  Pseudoexfoliation

          -  Known steroid IOP responder or ocular hypertension IOP &gt;25 mmHg by tonometry

          -  Retinal detachment within the last 6 months

          -  Anterior chamber depth less than 2.5 mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoopes Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve H Linn, OD</last_name>
    <role>Study Director</role>
    <affiliation>Hoopes Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoopes Vision</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report. 2009 Jan 28;(11):1-25.</citation>
    <PMID>19294964</PMID>
  </reference>
  <reference>
    <citation>Vasavada AR, Vasavada V, Vasavada VA, Praveen MR, Johar SR, Gajjar D, Arora AI. Comparison of the effect of torsional and microburst longitudinal ultrasound on clear corneal incisions during phacoemulsification. J Cataract Refract Surg. 2012 May;38(5):833-9. doi: 10.1016/j.jcrs.2011.11.050.</citation>
    <PMID>22520307</PMID>
  </reference>
  <reference>
    <citation>Georgescu D, Kuo AF, Kinard KI, Olson RJ. A fluidics comparison of Alcon Infiniti, Bausch &amp; Lomb Stellaris, and Advanced Medical Optics Signature phacoemulsification machines. Am J Ophthalmol. 2008 Jun;145(6):1014-1017. doi: 10.1016/j.ajo.2008.01.024. Epub 2008 Mar 17.</citation>
    <PMID>18343350</PMID>
  </reference>
  <reference>
    <citation>Dooley IJ, O'Brien PD. Subjective difficulty of each stage of phacoemulsification cataract surgery performed by basic surgical trainees. J Cataract Refract Surg. 2006 Apr;32(4):604-8.</citation>
    <PMID>16698480</PMID>
  </reference>
  <reference>
    <citation>Gimbel HV, Neuhann T. Development, advantages, and methods of the continuous circular capsulorhexis technique. J Cataract Refract Surg. 1990 Jan;16(1):31-7.</citation>
    <PMID>2299571</PMID>
  </reference>
  <reference>
    <citation>Friedman NJ, Palanker DV, Schuele G, Andersen D, Marcellino G, Seibel BS, Batlle J, Feliz R, Talamo JH, Blumenkranz MS, Culbertson WW. Femtosecond laser capsulotomy. J Cataract Refract Surg. 2011 Jul;37(7):1189-98. doi: 10.1016/j.jcrs.2011.04.022. Erratum in: J Cataract Refract Surg. 2011 Sep;37(9):1742.</citation>
    <PMID>21700099</PMID>
  </reference>
  <reference>
    <citation>Artzén D, Lundström M, Behndig A, Stenevi U, Lydahl E, Montan P. Capsule complication during cataract surgery: Case-control study of preoperative and intraoperative risk factors: Swedish Capsule Rupture Study Group report 2. J Cataract Refract Surg. 2009 Oct;35(10):1688-93. doi: 10.1016/j.jcrs.2009.05.026.</citation>
    <PMID>19781460</PMID>
  </reference>
  <reference>
    <citation>Bellini LP, Brum GS, Grossi RS, Borowsky C. Cataract surgery complication rates. Ophthalmology. 2008 Aug;115(8):1432; author reply 1432-3. doi: 10.1016/j.ophtha.2008.04.009.</citation>
    <PMID>18675698</PMID>
  </reference>
  <reference>
    <citation>Richard J, Hoffart L, Chavane F, Ridings B, Conrath J. Corneal endothelial cell loss after cataract extraction by using ultrasound phacoemulsification versus a fluid-based system. Cornea. 2008 Jan;27(1):17-21. doi: 10.1097/ICO.0b013e3181583115.</citation>
    <PMID>18245961</PMID>
  </reference>
  <reference>
    <citation>Hayashi K, Hayashi H, Nakao F, Hayashi F. Risk factors for corneal endothelial injury during phacoemulsification. J Cataract Refract Surg. 1996 Oct;22(8):1079-84.</citation>
    <PMID>8915805</PMID>
  </reference>
  <reference>
    <citation>Uy HS, Edwards K, Curtis N. Femtosecond phacoemulsification: the business and the medicine. Curr Opin Ophthalmol. 2012 Jan;23(1):33-9. doi: 10.1097/ICU.0b013e32834cd622. Review.</citation>
    <PMID>22081031</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoopes Vision</investigator_affiliation>
    <investigator_full_name>Steve H. Linn, OD</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

